Entering text into the input field will update the search result below
Try for free
Search for Symbols, analysts, keywords

Stereotaxis stock rises after pact with Abbott to improve abnormal heartbeat treatment

May 19, 2023 9:20 AM ETStereotaxis, Inc. (STXS), ABTBy: Ravikash, SA News Editor5 Comments
Two confident business man shaking hands during a meeting in the office, success, dealing, greeting and partner in sun light

nuttapong punna

  • Stereotaxis (NYSE:STXS) is collaborating with Abbott Laboratories (NYSE:ABT) to combine mapping and robotic technologies to improve treatment of abnormal heart rhythms.
  • The partnership will integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems.
  • The companies said the combination of Abbott's cardiac mapping system with Stereotaxis' robotic technology brings together detailed real-time diagnostic information with precision and stability of robotics during therapy delivery.
  • The integrated technologies are cleared for use in Europe with additional regulatory clearances expected in the coming months, the companies noted.
  • STXS +8.88% to $1.84 premarket May 19

  • More on Abbott

  • Abbott Remains A Top Pick For Dividend Investors

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.